Lilly's Foundayo Obesity Pill Reaches 7,000+ Prescriptions in Week 4, Uptake Remains Modest
LLY sits 56% above its 52-week low of $623.78.
Summary
Eli Lilly's new oral obesity drug, Foundayo, recorded over 7,000 prescriptions in its fourth week in the U.S. This data point continues the trend of 'modest uptake' previously reported for its second week, with analysts noting the current pace is below the approximately 22,000 weekly prescriptions needed to hit consensus expectations for $160 million in second-quarter sales. While some investors may look beyond initial weekly metrics, these early numbers are a critical indicator of market penetration for a highly anticipated growth driver. Continued modest uptake could temper near-term revenue expectations for Foundayo. Traders will closely monitor future prescription data and company updates on the drug's commercial ramp-up.
At the time of this announcement, LLY was trading at $976.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $918.2B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.